PCI Biotech: Invitation to Q3 2022 results presentation
17 Noviembre 2022 - 10:42AM
PCI Biotech: Invitation to Q3 2022 results presentation
Oslo, Norway, 17 November 2022 - PCI Biotech
(OSE: PCIB) invites to an online presentation of the company's Q3
2022 interim report on Wednesday 23 November 2022, 08:30am –
09:30am CET (local time).
The presentation will be held as a live webcast
and can be accessed through www.pcibiotech.com. There will be a
Q&A session at the end of the presentation and it will be
possible to post written questions through the webcast console or
through a teleconference facilitated for attendees intending to ask
questions verbally during the Q&A session.
The company will be represented by Ronny
Skuggedal (CEO/CFO), Anders Høgset (CSO), and Morten Luhr (BD
Manager) and the presentation will be held in Norwegian.
PCI Biotech’s Q3 2022 interim report will be
released on 23 November 2022 at 07.00am CET. The interim report and
presentation will be made available on www.newsweb.no and on the
company's webpage, www.pcibiotech.com.
For further information, please contact:Ronny
Skuggedal, CEO / CFOEmail: rs@pcibiotech.noMobile: +47 9400
5757
About PCI
Biotech PCI
Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies through its innovative
photochemical internalisation (PCI) technology platform. PCI
induces triggered endosomal release that is used to unlock the true
potential of therapeutic modalities.
The fimaVacc
programme aims to enhance immunotherapy in cancer, by triggered
endosomal release of antigens or nucleic acids encoding antigens,
or immunostimulatory factors. In the
fimaNAc programme endosomal
release is utilised to provide intracellular delivery of nucleic
acids, such as mRNA and RNAi therapeutics, thereby addressing one
of the major bottlenecks facing this emerging and promising
field.
For further information, please visit:
www.pcibiotech.com Contact
information: PCI Biotech Holding ASA, Ullernchausséen 64,
N-0379
Oslo
Forward-looking
statements This
announcement may contain forward-looking statements, which as such
are not historical facts, but are based upon various assumptions,
many of which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
This information is subject to the disclosure
requirements pursuant to section 5-12 of the Norwegian Securities
Trading Act.
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024